Neuroprotective Effect of the Endogenous Amine 1MeTIQ in an Animal Model of Parkinson’s Disease by Agnieszka Wąsik et al.
ORIGINAL ARTICLE
Neuroprotective Effect of the Endogenous Amine 1MeTIQ
in an Animal Model of Parkinson’s Disease
Agnieszka Wa˛sik1 • Irena Roman´ska1 • Jerzy Michaluk1 • Agnieszka Zelek-Molik2 •
Irena Nalepa2 • Lucyna Antkiewicz-Michaluk1
Received: 29 May 2015 / Revised: 31 July 2015 / Accepted: 12 August 2015 / Published online: 25 August 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Parkinson’s disease (PD) is a neurodegenera-
tive disorder that is hallmarked by pathological changes
associated with the death of dopaminergic neurons, par-
ticularly in the extrapyramidal system (substantia nigra
pars compacta, striatum) of the brain. Although the causes
of slow neuronal death in PD are unknown, both genetic
and environmental factors are likely involved. Endogenous
isoquinolines, such as 1-benzyl-1,2,3,4-tetrahydroiso-
quinoline (1BnTIQ), present in the human brain have been
previously reported to participate in the pathogenesis of
PD. The chronic administration of 1BnTIQ induced
parkinsonism in primates, and this effect might be associ-
ated with idiopathic PD. However, another endogenous
derivative of tetrahydroisoquinoline, 1-methyl-1,2,3,4-te-
trahydroisoquinoline (1MeTIQ), displays clear neuropro-
tective properties in the brain. In the present study, we
investigated the neuroprotective effects of 1MeTIQ (25 and
50 mg/kg) in an animal model of PD after the chronic
administration of 1BnTIQ (25 mg/kg). Behavioral analyses
demonstrate that both acute and repeated treatment with
1MeTIQ completely antagonized 1BnTIQ-induced changes
in rat locomotor activity. Neurochemical experiments
indicate that 1MeTIQ co-administered with 1BnTIQ com-
pletely antagonized 1BnTIQ-induced reduction in the
dopamine (DA) concentration in rat brain structures. In
conclusion, the results demonstrate that 1MeTIQ possesses
important neuroprotective properties in the animal model




disease  Dopamine metabolism
Introduction
Tetrahydroisoquinolines, e.g., salsolinol and 1-benzyl-
1,2,3,4-tetrahydroisoquinoline (1BnTIQ), are a group of
endogenous compounds with neurotoxic properties. How-
ever, one derivative from this group, 1-methyl-1,2,3,4-te-
trahydroisoquinoline (1MeTIQ), exhibits neuroprotective
properties. It has previously been shown that 1MeTIQ acts
as a reversible inhibitor of monoamino oxidase (MAO)
activity, blocks both the formation of 3,4-dihydrox-
yphenylacetic acid (DOPAC) and the production of free
radicals and shifts dopamine (DA) catabolism toward
COMT-dependent O-methylation. This mechanism might
be important for the neuroprotective activity of 1MeTIQ
(Antkiewicz-Michaluk et al. 2001; Patsenka and Antkie-
wicz-Michaluk 2004). Additionally, 1MeTIQ acts as a
natural scavenger of free radicals and interacts with the
agonistic conformation of dopamine receptors (An-
tkiewicz-Michaluk et al. 2006, 2007). However, another
endogenous amine present in the brain, 1BnTIQ, exhibits a
contrasting molecular mechanism because this molecule
enhances the rate of dopamine metabolism, activates the
dopamine oxidation pathway, and increases the production
of free radicals. In addition, 1BnTIQ inhibits the COMT-
dependent O-methylation pathway (Antkiewicz-Michaluk
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et al. 2001; Wa˛sik et al. 2009). Reflecting the neurotoxic
mechanism of 1BnTIQ, this compound is considered an
etiological factor of idiopathic Parkinson’s disease (PD)
(Kotake et al. 1995). Previous studies have demonstrated
that chronic treatment with 1BnTIQ produces parkinso-
nian-like symptoms in rodents and primates (Kotake et al.
1995; 2003; Kohta et al. 2010). In vitro studies indicated
that 1BnTIQ induces cell death via apoptosis and produces
an increase in the formation of the active caspase-3 protein
fragments (Shavali and Ebadi 2003). 1BnTIQ accumulates
in the dopaminergic neurons, where this molecule might
exert pathological effects that lead to parkinsonism. Kotake
et al. (1995) showed that the level of 1BnTIQ in the
cerebrospinal fluid (CSF) of parkinsonian patients was
three times higher than that in the CSF of the control group.
These data suggest that chronic treatment with a low dose
of 1BnTIQ might serve as an adequate animal model of the
progressive process of PD.
The aim of the present study was to investigate the
neuroprotective effects of 1MeTIQ in an animal model of
PD after the chronic administration of 1BnTIQ. Using
behavioral tests, we analyzed the influence of acute and
chronic treatment with 1MeTIQ on changes in rat loco-
motor activity induced through the repeated administration
of 1BnTIQ.
In neurochemical experiments, using high-performance
liquid chromatography (HPLC) methodology with elec-
trochemical detection, we investigated the effect of
1MeTIQ on disturbances in brain DA metabolism evoked
through 1BnTIQ. Additionally, the concentration of exci-
tatory amino acids (EAA) in the frontal cortex and the level
of a-synuclein and tyrosine hydroxylase (TH) in the sub-
stantia nigra were also detected.
Materials and Methods
Animals and Treatments
All experiments were performed in male Wistar rats with
an initial body weight of 220–240 g. All animals had free
access to standard laboratory food and tap water and were
kept at room temperature (22C) under an artificial light/-
dark cycle (12/12 h, light on at 7:00).
1BnTIQ was intraperitoneally (i.p.) administered at a
dose of 25 mg/kg chronically for 14 consecutive days. In
the mixed group, a single or chronic dose of 1MeTIQ (25
or 50 mg/kg i.p.) was administered 20 min before 1BnTIQ
administration. Control rats were treated with the appro-
priate vehicle. Rats were sacrificed through decapitation at
2 h after the last drug injections, and different brain
structures were dissected for further analysis. The experi-
ments were performed between 9:00 and 16:00.
All experimental procedures were performed in accor-
dance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and approved through
the Bioethics Commission as compliant with Polish Law.
All experimental procedures were approved through the
Local Bioethics Commission of the Institute of Pharma-
cology, Polish Academy of Sciences in Krako´w.
Drugs
1MeTIQ hydrochloride and 1BnTIQ hydrochloride were
synthesized (according to Cannon and Webster 1958) at the
Department of Drug Chemistry of the Institute of Phar-
macology, the Polish Academy of Sciences in Krakow. The
purity of the compound was verified by measuring the
melting point, and homogeneity was assessed using a
chromatographic column. The compounds were dissolved
in a 0.9 % NaCl solution.
Behavioral Study
Locomotor Activity
Locomotor activity was assessed using actometers (Opto-
Varimex activity monitors; Columbus Inst., USA) linked
on-line to a compatible IBM PC. Each cage
(43 9 44 9 25 cm) perimeter was lined with an array of
15 9 15 photocell beams located 3 cm from the floor
surface. Interruptions of the photocell beams were counted
as a measure of horizontal locomotor activity and defined
as the distance traveled (in cm). The rats were administered
an acute dose of 25 or 50 mg/kg (i.p.) 1MeTIQ (expression
treatment group) or as the last dose (14-day chronic
administration; development treatment group) at 20 min
before the last dose of 1BnTIQ (25 mg/kg i.p.; 14-day
chronic administration). Subsequently, the animals were
transferred to experimental cages, and locomotor activity
(horizontal activity, traveled distance in cm) and rearing
(vertical activity, time in sec) were recorded for 90 min
and analyzed using the Auto-Track Software Program




Dopamine Metabolism The rats were sacrificed through
decapitation 2 h after the last 1BnTIQ injection, and the
nucleus accumbens and striatum were immediately dis-
sected. The tissue was frozen on dry ice (-70 C) until
further use in a biochemical assay. The levels of dopamine
(DA) and its metabolites, 3,4-dihydroxyphenylacetic acid
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(DOPAC), 3-methoxytyramine (3-MT), and homovanillic
acid (HVA), were assayed through high-performance liq-
uid chromatography (HPLC) with electrochemical detec-
tion (Hewlett Packard 1049A). The tissue samples were
weighed and homogenized in ice-cold 0.1 M per-
chloroacetic acid containing 0.05 mM ascorbic acid. After
centrifugation (10,000g for 5 min), the supernatants were
filtered through RC 58 0.2-im cellulose membranes (Bio-
analytical Systems, West Lafayette, IN, USA). The HP
1050 chromatograph (Hewlett-Packard, Golden, CO, USA)
was equipped with C18 columns. The electrochemical cell
potential was 800 mV. The mobile phase comprised
0.05 M citrate–phosphate buffer (pH 3.5), 0.1 mM EDTA,
1 mM sodium octyl sulfonate, and 3.5 % methanol. The
flow rate was maintained at 1 ml/min. Dopamine and its
metabolites were quantified based on the chromatograph
peak height compared with standards run on the day of
analysis. Each group comprised seven animals.
Determination of Amino Acid Neurotransmitters The rats
were sacrificed through decapitation 2 h after the last
1BnTIQ injection, and the frontal cortex was immediately
dissected. The tissue was frozen on dry ice (-70 C) until
further use in a biochemical assay. The tissue was weighed,
and subsequently homogenized in 4 ml of chilled saline
solution (0.9 %). The homogenate was centrifuged at
22.000g for 10 min at 4 C. The supernatant was trans-
ferred and filtered through a 0.22-lm pore size Millipore
filter for derivatization. A 100-ll aliquot of mixed amino
acid solution or sample supernatant, 175 ll of borate buffer
solution, 200 ll of acetonitrile, and 25 ll NBD-F working
solution were mixed in a 1.5 ml centrifuge tube. The well
mixed solution was incubated in a 60 C water bath for
7 min in the dark. NBD-F reacts with amino group and
enables temperature, 10 ll of solution was injected into the
equilibrated HPLC system. The analysis was performed on
a Coulochem III HPLC system equipped with a UV DIO-
NEX UltiMate 3000 detector (472 nm). The analyte was
separated on an analytical Hypersil C18 column (250 mm
length 9 4.6 mm, 5 lm particle diameter) manufactured in
Germany. The mobile phase comprised a mixture of ace-
tonitrile–phosphate buffer (0.02 mol/l, pH 6.0; 16:84, v/v)
filtered through a 0.45-lm nylon filter and degassed under
ultrasound and vacuum for 30 min. The mobile phase was
delivered at a flow rate of 1.0 ml/min, and the column
temperature was set to 30 C.
Immunoblotting Protein was extracted through high-
speed shaking in plastic tubes with stainless steel beads in a
tissuelyser with 100 ll of ice-cold RIPA lysis buffer
(Sigma, USA), containing complete mini protease inhibitor
(Roche Diagnostics, USA). After incubation for 30 min,
the homogenates were centrifuged at 10,000g for 20 min at
4 C.The resulting supernatants were collected and sub-
jected to protein analysis using the Bicinchoninic Acid
Assay Kit (Sigma, USA). Equal amounts of protein extracts
(12 lg) were boiled in Laemmli buffer containing 5 % b-
mercaptoethanol for 5 min, separated through SDS-PAGE
(4–15 %), and transferred to nitrocellulose membranes.
The membranes were blocked with 5 % non-fat dry milk in
Tris-buffered saline containing Tween-20 (TBST;
pH = 7.6) for 1 h at room temperature and incubated with
a primary antibody against tyrosine hydroxylase (1:2,000;
Cell Signaling, USA) or a-synuclein (1:2,000; Cell Sig-
naling, USA) overnight at 4 C. After three washes with
blocking solution, the membranes were incubated with the
appropriate secondary antibodies for 1 h at room temper-
ature, followed by three washes with TBST. Antibody
binding was detected using an enhanced chemilumines-
cence kit (ECL Plus, Pierce, USA). Equal loading proteins
were further confirmed after probing with anti-calnexin
antiserum (CNX; 1:5,000; Enzo Life Sciences, USA) or
anti-b-actin antiserum (1:5,000; Sigma, USA). All Western
blot analyses were performed at least twice to confirm the
results. The chemiluminescence signal was visualized
using a Luminescent Image Analyzer Fuji-Las 4000 (Fuji,
Japan). Immunoreactive bands were quantified using an
image analyzer (ScienceLab, MultiGauge V3.0).
Calculations and Statistics
Two-way analysis of variance (ANOVA) for repeated
measures was used to analyze the results of the behavioral
test (locomotor activity). Differences between the control
and experimental groups were assessed using Duncan’s
post hoc test.
The comparison of the effects of acute and multiple
administration of 1BnTIQ and the effect of chronic
1MeTIQ administration on 1BnTIQ-produced changes in
the concentration of EAA were analyzed by one-way
ANOVA, followed by Duncan’s post hoc test. The results
of the biochemical experiments were analyzed using two-
way ANOVA, followed by Duncan’s post hoc test, when
appropriate. These indices were calculated using the con-
centrations of individual tissue samples (n = 6–7).
Results
Behavioral Study
The Effect of Acute 1MeTIQ Administration on 1BnTIQ-
Induced Hyperactivity in Rats
The acute administration of 1MeTIQ (50 mg/kg i.p.)
induced a significant reduction in the horizontal
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exploratory activity of rats (P\ 0.01). In addition, the
chronic administration of 1BnTIQ (25 mg/kg i.p.) pro-
duced a significant (P\ 0.05) elevation of exploratory
activity (Fig. 1a). In the mixed group, an acute dose of
1MeTIQ completely antagonized 1BnTIQ-induced
hyperactivity.
The Effect of Chronic 1MeTIQ Administration on 1BnTIQ-
Induced Hyperactivity in Rats
As shown in Fig. 1b, the chronic administration of
1MeTIQ (50 mg/kg i.p.) over 14 days induced a significant
(P\ 0.01) decrease in exploratory activity. The multiple
(14-day) administration of 1BnTIQ at a low dose of 25 mg/
kg (i.p.) significantly increased (P\ 0.05) the exploratory
activity during the first 30 min of measurement. In the
mixed group, 1MeTIQ completely antagonized 1BnTIQ-
induced hyperactivity (Fig. 1b).
Biochemical Studies
Ex Vivo Experiments
The Comparison of the Effects of the Acute and Multiple
Administration of 1BnTIQ on Dopamine Metabolism in Rat
Brain Structures One-way ANOVA demonstrated a sig-
nificant effect of 1BnTIQ treatment (F[2,18] = 18.61,
P\ 0.01) on the level of DA in the striatum (Table 1).
Duncan’s post hoc analysis demonstrated that both the
acute and multiple administration of 1BnTIQ significantly
decreased the level of DA (respectively, 40 and 25 %;
P\ 0.01). The statistical analysis indicated no effect of
1BnTIQ treatment (F[2,18] = 1.31, N.S.) on DOPAC
concentration (Table 1). One-way ANOVA demonstrated a
significant effect of 1BnTIQ treatment (F[2,18] = 5.81,
P\ 0.05) on the level of 3-MT in the striatum (Table 1).
The post hoc analysis showed that the acute injection of
1BnTIQ reduced the concentration of 3-MT in the rat
striatum (approximately 25 %, P\ 0.05). The statistical
analysis indicated a significant effect of 1BnTIQ treatment
(F[2,18] = 4.81, P\ 0.05) on the HVA concentration
(Table 1). Duncan’s post hoc analysis demonstrated that
the acute administration of 1BnTIQ significantly increased
the level of HVA (approximately 60 %; P\ 0.05).
One-way ANOVA indicated a significant effect of
1BnTIQ treatment (F[2,18] = 18.73, P\ 0.01) on the
level of DA in the nucleus accumbens (Table 1). The post
hoc test showed that both the acute and multiple adminis-
tration of 1BnTIQ significantly decreased the level of DA
(respectively, 40 and 30 %; P\ 0.01). Treatment with
1BnTIQ (F[2,18] = 7.64, P\ 0.01) significantly affected
the DOPAC concentration in the nucleus accumbens
(Table 1). Duncan’s post hoc analysis demonstrated that
the multiple administration of 1BnTIQ significantly
decreased the level of DOPAC (approximately 25 %;
P\ 0.01). One-way ANOVA indicated a significant effect
of 1BnTIQ treatment (F[2,18] = 10.26, P\ 0.01) on the
3-MT concentration in the nucleus accumbens (Table 1).
The post hoc test showed that both acute and multiple
administration of 1BnTIQ significantly decreased the level
of 3-MT (respectively 40 and 30 %; P\ 0.01). The sta-
tistical analysis indicated a significant effect of 1BnTIQ
treatment (F[2,18] = 4.81, P\ 0.05) on the HVA con-
centration (Table 1). Duncan’s post hoc analysis demon-
strated that the acute administration of 1BnTIQ
significantly increased the level of HVA (approximately
20 %; P\ 0.05).
The Effect of Acute 1MeTIQ Administration on Changes in
Dopamine Metabolism Induced After the Chronic Admin-
istration of 1BnTIQ in Rat Brain Structures
Table 2 Striatum
Fig. 1 The influence of acute (a) and chronic (b) treatment with
1MeTIQ on changes in exploratory activity induced by chronic
administration of 1BnTIQ. 1BnTIQ (25 mg/kg i.p.) was administered
chronic during 14 consecutive days. 1MeTIQ (50 mg/kg i.p) was
given acute (a) or chronic during 14 consecutive days (b). In the
mixed group, 1MeTIQ was injected 20 min before 1BnTIQ admin-
istration. A control group was treated by saline. Rats were placed into
actometers immediately after last drugs administration. Movements
were recorded for 30 min. The data are expressed as the mean-
s ± SEM (n = 7 animals). Data were analyzed with a two-way
ANOVA for repeated measures, followed by Duncan’s post hoc test.
Statistical significance: * P\ 0.05; ** P\ 0.01 versus saline-treated
group; ? P\ 0.05 versus 1BnTIQ-treated group
354 Neurotox Res (2016) 29:351–363
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Two-way ANOVA indicated a significant effect of chronic
treatment with 1BnTIQ (F[2,35] = 29.41, P\ 0.01) and
an acute dose of 1MeTIQ (F[2,35] = 8.88, P\ 0.01) on
the DA concentration in the striatum (Table 2). The
interaction between 1BnTIQ and 1MeTIQ treatment was
not significant (F[2,35] = 0.79, N.S.). Duncan’s post hoc
analysis demonstrated that the multiple administration of
1BnTIQ significantly decreased the level of DA (approxi-
mately 25 %; P\ 0.01). In contrast, 1MeTIQ co-admin-
istered with the last dose of 1BnTIQ completely
antagonized the 1BnTIQ-induced reduction in DA (the DA
level remained similar to the control level) (Table 2).
Two-way ANOVA demonstrated a significant effect of
1BnTIQ (F[2,35] = 5.11, P\ 0.05) and 1MeTIQ
(F[2,35] = 64.73, P\ 0.01) on the DOPAC concentration
in the striatum (Table 2). The interaction between 1BnTIQ
and 1MeTIQ was not significant (F[2,35] = 0.01, N.S.).
The post hoc analysis indicated that the acute administra-
tion of 1MeTIQ (at both doses examined) decreased the
DOPAC concentration (approximately 30 and 45 %;
P\ 0.01) and that this effect was enhanced in the mixed
groups (approximately 40 and 55 %) (Table 2).
The statistical analysis showed no effect of 1BnTIQ
(F[2,35] = 0.5, N.S.) or the interaction between 1BnTIQ
and 1MeTIQ (F[2,35] = 0.09; N.S.) on the levels of 3-MT
in the rat striatum. In contrast, the effect of 1MeTIQ was
significant (F[2,35] = 36.49, P\ 0.01) (Table 2). Dun-
can’s post hoc test showed that both doses of 1MeTIQ
administered alone increased the 3-MT concentration (re-
spectively, 50 and 70 %, P\ 0.01), and similar effects
were observed in the mixed groups (Table 2).
Treatment with 1BnTIQ (F[2,35] = 20.97, P\ 0.01)
and 1MeTIQ (F[2,35] = 18.87, P\ 0.01) significantly
affected the HVA concentration in the striatum (Table 2).
This analysis also revealed a significant interaction
between 1BnTIQ and 1MeTIQ (F[2,35] = 14.88,
P\ 0.01). The post hoc analysis showed that the chronic
administration of 1BnTIQ significantly increased the level
of HVA (approx. 35 %, P\ 0.05), and this effect was
completely blocked through the administration of both
concentrations of 1MeTIQ (Table 2).
Two-way ANOVA demonstrated that chronic treatment
with 1BnTIQ significantly increased the rate of DA oxi-
dation, measured as index [DOPAC]/[DA] (P\ 0.01).
This effect was completely inhibited through the acute
administration of 1MeTIQ at both doses examined
(Fig. 2a). Similarly, the rate of total DA catabolism
(measured as index [HVA]/[DA]) was significantly
(P\ 0.01) increased after the multiple administration of
1BnTIQ, and this effect was antagonized with a single dose
of 1MeTIQ (Fig. 2b).
Nucleus Accumbens
Two-way ANOVA indicated a significant effect of both
1BnTIQ (F[2,35] = 17.97, P\ 0.01) and 1MeTIQ
(F[2,35] = 4.4, P\ 0.01) treatments on the DA concen-
tration in the nucleus accumbens (Table 2). In addition, the
interaction between 1BnTIQ and 1MeTIQ was not signif-
icant (F[2,35] = 1.17, N.S.). Duncan’s post hoc test
showed that the chronic administration of 1BnTIQ
Table 1 The comparison of the
influence of acute and chronic
administration of 1BnTIQ on











Saline 7 9894 ± 618 2158 ± 113 416 ± 30 1027 ± 90
1BnTIQ/25-19 7 5817 ± 415** 1897 ± 83 316 ± 14** 1638 ± 171**
1BnTIQ/25-149 7 7416 ± 356**? 1999 ± 142 388 ± 16? 1383 ± 146









Saline 7 9.089 ± 406 2.742 ± 98 320 ± 19 1.049 ± 69
1BnTIQ/25-19 7 5.656 ± 505** 2.408 ± 180 195 ± 24** 1.245 ± 141*
1BnTIQ/25-149 7 6.172 ± 358** 2.024 ± 94**? 233 ± 16** 926 ± 53?








1BnTIQ (25 mg/kg i.p.) was administered acute or chronically during 14 consecutive days. Rats were
decapitated 2 h after the injections. The results are expressed as the means ± SEM of seven samples
(n = 7 animals per group). Data were analyzed with a one-way ANOVA followed by Duncan’s post hoc
test. Statistical significance: * P\ 0.05; ** P\ 0.01 versus Saline group; ? P\ 0.05 versus acute
1BnTIQ group
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decreased the DA concentration (approx. 30 %, P\ 0.01).
Both concentrations of 1MeTIQ partially antagonized this
effect (Table 2).
The statistical analysis showed a significant effect of
1BnTIQ (F[2,35] = 25.95, P\ 0.01) and 1MeTIQ
(F[2,35] = 54.39, P\ 0.01) treatments on the DOPAC
levels. In contrast, the interaction between 1BnTIQ and
1MeTIQ (F[2,35] = 1.86, N.S.) was not significant
(Table 2). The post hoc analysis demonstrated a reduction
in the level of DOPAC through chronic treatment with
1BnTIQ (approximately 25 %), and both doses of 1MeTIQ
(respectively, 40 and 50 %). In the mixed groups, this
reduction was markedly enhanced (respectively, 50 and
60 %). (Table 2).
Two-way ANOVA further revealed no effect of the
chronic administration of 1BnTIQ (F[2,35] = 0.27, N.S.)
on the 3-MT concentration in the nucleus accumbens
(Table 2). However, the effects of 1MeTIQ (F[2,35] =
17.01, P\ 0.01) and the interaction between 1BnTIQ and
1MeTIQ were significant (F[2,35] = 3.74, P\ 0.05).
Duncan’s post hoc test showed that chronic treatment with
1BnTIQ (25 mg/kg) reduced the levels of 3-MT (approx-
imately 30 %), and this effect was completely blocked
using both doses of 1MeTIQ (Table 2).The statistical
analysis indicated a significant effect of 1BnTIQ
(F[2,35] = 8.75, P\ 0.01) and 1MeTIQ (F[2,35] = 5.80,
P\ 0.01) treatments on the HVA levels, but the interac-
tion between 1BnTIQ and 1MeTIQ (F[2,35] = 0.19, N.S.)
was not significant. The post hoc analysis showed that
treatment with 1BnTIQ concomitant with 1MeTIQ signif-
icantly reduced the HVA levels (approximately 35 %)
(Table 2).
Table 2 The influence of acute administration of 1MeTIQ on changes induced by chronic treatment with 1BnTIQ in the concentration of
dopamine (DA) and its metabolites
Treatment N DA (ng/g) DOPAC (ng/g) 3-MT (ng/g) HVA (ng/g)
Acute Chronic
Striatum
Saline Saline 7 9894 ± 618 2158 ± 113 416 ± 30 1027 ± 90
1MeTIQ/25 Saline 7 11055 ± 264 1432 ± 61** 620 ± 34** 288 ± 27**
1MeTIQ/50 Saline 7 10979 ± 502 1144 ± 47** 706 ± 38** 1049 ± 87
Saline MeTIQ/25 6 7416 ± 356** 1999 ± 142 388 ± 16 1383 ± 146*
1MeTIQ/25 1BnTIQ/25 7 9649 ± 542?? 1254 ± 64**?? 587 ± 45**?? 1072 ± 58?
1MeTIQ/25 1BnTIQ/25 7 9105 ± 118?? 968 ± 79**?? 703 ± 44**?? 881 ± 60??

























Saline Saline 7 9089 ± 406 2742 ± 98 320 ± 19 1049 ± 69
1MeTIQ/25 Saline 7 9796 ± 388 1742 ± 89** 386 ± 18 901 ± 71
1MeTIQ/50 Saline 7 9765 ± 1145 1406 ± 204** 402 ± 47 854 ± 129
Saline 1BnTIQ/25 6 6172 ± 358** 2024 ± 94** 233 ± 16* 926 ± 53
1MeTIQ/25 1BnTIQ/25 7 8316 ± 413? 1378 ± 85**?? 373 ± 24?? 693 ± 44**?
1MeTIQ/50 1BnTIQ/25 7 8351 ± 476? 1080 ± 95**?? 467 ± 34**?? 664 ± 56**?
























1BnTIQ was chronically administered (25 mg/kg i.p.) during 14 consecutive days. In the mixed group, 1MeTIQ (50 mg/kg i.p.) was given once,
20 min before last 1BnTIQ administration. Rats were decapitated 2 h after the injections. The results are expressed as the means ± SEM of six
to seven samples (n = 6–7 animals per group). Data were analyzed with a two-way ANOVA followed by Duncan’s post hoc test. Statistical
significance: * P\ 0.05; ** P\ 0.01 versus Saline/Saline group; ? P\ 0.05, ??P\ 0.01 versus 1BnTIQ group
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The Effect of Chronic 1MeTIQ Administration on Changes
in Dopamine Metabolism Induced Through the Chronic
Administration of 1BnTIQ in Rat Brain Structures
Table 3 Striatum
Two-way ANOVA revealed a significant effect of chronic
treatment with 1BnTIQ (F[2,36] = 41.37, P\ 0.01) and
the chronic administration of 1MeTIQ (F[2,36] = 10.18,
P\ 0.01) on the DA concentration in the striatum
(Table 3). There was no significant interaction between the
chronic administration of 1BnTIQ and multiple injections
with 1MeTIQ (F[2,36] = 2.01, N.S.). Duncan’s post hoc
test showed that the chronic administration of 1BnTIQ
reduced the DA concentration (approximately 25 %;
P\ 0.01), while the multiple administration of 1MeTIQ
(in both doses) increased neurotransmitter (by 20 %;
P\ 0.05). Additionally, when the chronic administration
of 1BnTIQ (25 mg/kg) was coupled with the chronic
administration of 1MeTIQ, the concentration of dopamine
returned to the control level (Table 3).
Two-way ANOVA demonstrated a significant effect
of chronic treatment with 1BnTIQ (F[2,36] = 6.49,
P\ 0.01) and the multiple administration of 1MeTIQ
(F[2,36] = 104.27, P\ 0.01) on the DOPAC concentra-
tion in the striatum (Table 3). Notably, the interaction
between 1BnTIQ and 1MeTIQ was not significant
(F[2,36] = 0.11, N.S.). The post hoc analysis showed that
chronic 1MeTIQ administration strongly decreased the
DOPAC concentration (respectively, 40 and 55 %;
P\ 0.01); this effect was enhanced in the mixed group
(respectively, 55 and 65 %; P\ 0.01) (Table 3).
The statistical analysis revealed no effect of chronic
treatment with 1BnTIQ (F[2,36] = 0.48, N.S.) on the level
of 3-MT (Table 3). Chronic treatment with 1MeTIQ
(F[2,36] = 70.6, P\ 0.01) significantly affected the 3-MT
concentration. There was no interaction between the
chronic administration of 1BnTIQ and the multiple
administration of 1MeTIQ (F[2,36] = 0.41, N.S.). Dun-
can’s post hoc test showed that chronic treatment with
1MeTIQ (in both doses) increased the 3-MT concentration
(approximately 145 and 180 %; P\ 0.01). A similar effect
was observed with the chronic administration of 1BnTIQ
(25 mg/kg) coupled with the chronic administration of
1MeTIQ, (Table 3).
Two-way ANOVA demonstrated no effect of chronic
1BnTIQ treatment (F[2,36] = 1.18, N.S.) on the HVA
Fig. 2 The influence of acute
(a) and chronic
(b) administration of 1MeTIQ
on the elevation rate of
dopamine oxidation induced by
chronic treatment with 1BnTIQ.
1BnTIQ (25 mg/kg i.p.) was
administered chronic during 14
consecutive days. 1MeTIQ (25
or 50 mg/kg i.p) was given
acute (a) or chronic during 14
consecutive days (b). In the
mixed group, 1MeTIQ was
injected 20 min before 1BnTIQ
administration. A control group
was treated by saline. Rats were
decapitated 2 h after the
injections. The data are
expressed as the means ± SEM
(n = 6–7 animals). Data were
analyzed with a two-way
ANOVA, followed by Duncan’s
post hoc test. Statistical
significance: * P\ 0.05;
** P\ 0.01 versus saline-
treated group; ?? P\ 0.01
versus 1BnTIQ-treated group
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concentration in the striatum (Table 3). In contrast, the
chronic administration of 1MeTIQ(F[2,36] = 11.65,
P\ 0.01) significantly affected the level of HVA. An
interaction between 1BnTIQ and 1MeTIQ was also
detected (F[2,36] = 4.47, P\ 0.01). The post hoc analysis
showed that 1BnTIQ increased the HVA concentration
(approximately 135 %; P\ 0.01); this effect was com-
pletely blocked through chronic treatment with both con-
centrations of 1MeTIQ (Table 3).
Two-way ANOVA indicated that repeated treatment
with 1BnTIQ significantly increased the rate of DA oxi-
dation measured as index [DOPAC]/[DA] (P\ 0.01). This
effect was completely inhibited through the chronic
administration of 1MeTIQ at both doses examined
(Fig. 3a). Similarly, the rate of total DA catabolism
(measured as index [HVA]/[DA]) was significantly
(P\ 0.01) increased through the multiple administration
of 1BnTIQ, and this effect was antagonized through the
chronic administration of 1MeTIQ (Fig. 3b).
Nucleus Accumbens
Two-way ANOVA revealed a significant effect of chronic
1BnTIQ treatment (F[2,36] = 26.21, P\ 0.01) on the DA
concentration in the nucleus accumbens (Table 3). In
contrast, multiple 1MeTIQ administration produced no
effect on the level of DA (F[2,36] = 2.43, N.S.). The
statistical analysis revealed a significant interaction
between the chronic administration of 1BnTIQ and
1MeTIQ (F[2,36] = 3.98, P\ 0.05). The post hoc test
indicated that the multiple injection of 1BnTIQ decreased
the level of DA (approximately 30 %, P\ 0.01) and that
Table 3 The influence of chronic administration of 1MeTIQ on changes induced by chronic treatment with 1BnTIQ in the concentration of
dopamine (DA) and its metabolites
Treatment N DA (ng/g) DOPAC (ng/g) 3-MT (ng/g) HVA (ng/g)
Chronic Chronic
Striatum
Saline Saline 7 9894 ± 618 2158 ± 113 416 ± 30 1027 ± 90
1MeTIQ/25 Saline 7 11441 ± 254* 1255 ± 59** 603 ± 17** 930 ± 47
1MeTIQ/50 Saline 7 11259 ± 579* 976 ± 55** 737 ± 35** 868 ± 48
Saline 1BnTIQ/25 7 7416 ± 356** 1999 ± 142 388 ± 16 1383 ± 146**
1MeTIQ/25 1BnTIQ/25 7 8390 ± 239* 1029 ± 49**?? 616 ± 19**?? 853 ± 59??
1MeTIQ/50 1BnTIQ/25 7 9924 ± 416?? 823 ± 51**?? 705 ± 37**?? 807 ± 53??

























Saline Saline 7 9089 ± 406 2742 ± 98 320 ± 19 1049 ± 69
1MeTIQ/25 Saline 7 9552 ± 669 1295 ± 105** 354 ± 25 689 ± 79**
1MeTIQ/50 Saline 7 8892 ± 363 1050 ± 60** 405 ± 29* 593 ± 33**
Saline 1BnTIQ/25 7 6172 ± 358** 2024 ± 94** 233 ± 16* 926 ± 53
1MeTIQ/25 1BnTIQ/25 7 6971 ± 373**?? 1038 ± 74**?? 369 ± 22?? 518 ± 43**??
1MeTIQ/50 1BnTIQ/25 7 8442 ± 581?? 871 ± 77**?? 393 ± 28*?? 509 ± 24**??
























1BnTIQ was chronically administered (25 mg/kg i.p.) during 14 consecutive days. In the mixed group, 1MeTIQ (50 mg/kg i.p.) was given also
chronically, 20 min before each 1BnTIQ administration. Rats were decapitated 2 h after the injections. The results are expressed as the
means ± SEM of seven samples (n = 7 animals per group). Data were analyzed with a two-way ANOVA followed by Duncan’s post hoc test.
Statistical significance: * P\ 0.05; ** P\ 0.01 versus Saline/Saline group; ? P\ 0.05; ?? P\ 0.01 versus 1BnTIQ group
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this effect was antagonized after chronic treatment with
1MeTIQ (Table 3).
Two-way ANOVA demonstrated a significant effect of
chronic treatment with 1BnTIQ (F[2,36] = 29.92,
P\ 0.01) and the multiple administration of 1MeTIQ
(F[2,36] = 159.28, P\ 0.01) on the DOPAC concentra-
tion in rat nucleus accumbens (Table 3). An interaction
between 1BnTIQ and L-DOPA was also detected
(F[2,36] = 5.74, P\ 0.01). The post hoc analysis showed
that chronic injections of both 1BnTIQ and 1MeTIQ
reduced the DOPAC concentration (respectively, 25, 55
and 60 %; P\ 0.01); this effect was intensified in the
mixed groups (respectively, 65 and 70 %) (Table 3).
Two-way ANOVA revealed no effect of the chronic
administration of 1BnTIQ (F[2,36] = 2.05, N.S.) on the
level of 3-MT in the nucleus accumbens. The same sta-
tistical analysis indicated that chronic treatment with
1MeTIQ (F[2,36] = 14.17, P\ 0.01) significantly affec-
ted the 3-MT concentration (Table 3). The statistical
analysis revealed no interaction between 1BnTIQ and
1MeTIQ (F[2,36] = 2.48, N.S.). Duncan’s post hoc test
showed that multiple treatment with 1BnTIQ decreased the
level of 3-MT (approximately 30 %; P\ 0.05), and this
effect was reversed through chronic treatment at both
concentrations of 1MeTIQ (Table 3).
Two-way ANOVA revealed a significant effect of
chronic treatment with both 1BnTIQ (F[2,36] = 8.25,
P\ 0.01) and 1MeTIQ (F[2,36] = 39.26, P\ 0.01) on
the HVA concentration in the nucleus accumbens
(Table 3). The interaction between the chronic adminis-
tration of 1BnTIQ and chronic treatment with 1MeTIQ was
not significant (F[2,36] = 0.33, N.S.). The post hoc anal-
ysis demonstrated that chronic treatment with both doses of
1MeTIQ strongly decreased the HVA concentration (re-
spectively, 30 and 40 %; P\ 0.01); this effect was inten-
sified in the mixed groups (approximately 50 %) (Table 3).
The Effect of Chronic 1MeTIQ Administration on 1BnTIQ-
Produced Changes in the Concentration of EAA in the Rat
Frontal Cortex (Table 4) One-way ANOVA demon-
strated a significant effect of treatment (F[6,35] = 4.77,
P\ 0.01) on the concentration of aspartate in the frontal
cortex (Table 4). Duncan’s post hoc test showed that the
chronic administration of 1BnTIQ increased the aspartate
Fig. 3 The influence of acute
(a) and chronic
(b) administration of 1MeTIQ
on the elevation rate of
dopamine catabolism induced
by chronic treatment with
1BnTIQ. 1BnTIQ (25 mg/kg
i.p.) was administered chronic
during 14 consecutive days.
1MeTIQ (25 or 50 mg/kg i.p)
was given acute (a) or chronic
during 14 consecutive days (b).
In the mixed group, 1MeTIQ
was injected 20 min before
1BnTIQ administration. A
control group was treated by
saline. Rats were decapitated
2 h after the injections. The data
are expressed as the
means ± SEM (n = 6–7
animals). Data were analyzed
with a two-way ANOVA,
followed by Duncan’s post hoc
test. Statistical significance:
* P\ 0.05; ** P\ 0.01 versus
saline-treated group;
?? P\ 0.01 versus 1BnTIQ-
treated group
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concentration (approximately 125 %; P\ 0.01) and that
this effect was completely inhibited through the chronic
administration of 1MeTIQ (P\ 0.01). The statistical
analysis revealed no effect of treatment (F[6,35] = 1.65,
N.S.) on the level of glutamate in the frontal cortex
(Table 4). However, post hoc analysis indicated that the
chronic administration of 1BnTIQ increased the concen-
tration of glutamate (P\ 0.05) and that this effect was
blocked through the multiple administration of 1MeTIQ
(25 mg/kg i.p.) (Table 4).
Immunoblotting
Figure 4 shows that the acute administration of 1BnTIQ
(25 mg/kg i.p.) did not change the level of a-synuclein in
the substantia nigra, whereas the multiple administration of
1BnTIQ weakly (not significant) elevated the a-synuclein
concentration. A similar effect (non-significant increase in
the level of a-synuclein) was observed after the chronic
administration of 1MeTIQ (50 mg/kg i.p.) and in the
combined group (Fig. 4).
As demonstrated in Fig. 5, neither acute nor chronic
treatment with 1BnTIQ (25 mg/kg i.p.) changed the con-
centration of tyrosine hydroxylase. In addition, treatment
with 1MeTIQ (50 mg/kg i.p.) alone and concomitant with
1BnTIQ did not influence the level of tyrosine hydroxylase
(Fig. 5).
Discussion
The chronic administration of 1BnTIQ induced parkin-
sonism in primates, and this effect might reflect idiopathic
Parkinson’s disease (PD) (Abe et al. 2005). The neurotoxin
1BnTIQ causes parkinsonism in humans, and this molecule
is present in the cerebrospinal fluid of parkinsonian patients
at approximately three times the concentration detected in
healthy individuals (Kotake et al. 1995). These data clearly
demonstrated that chronic treatment with a low dose of
1BnTIQ could represent a good animal model of PD.
Distinct disturbances in the function of dopamine neurons
generated through the repeated administration of 1BnTIQ
might imitate the progressive character of PD. The results
obtained in the present study confirm those of earlier
studies and show that both the acute and chronic admin-
istration of 1BnTIQ significantly disturbed dopamine (DA)
Table 4 The influence of
chronic treatment with 1MeTIQ
and 1BnTIQ on the
concentration of aspartate
(ASP) and glutamate (GLU) in
rat front al cortex
Treatment N ASP (ng/20 ll) GLU (ng/20 ll)
Frontal cortex
Saline 5 464 ± 15 1998 ± 53
1BnTIQ/25 9 1 7 447 ± 17 2005 ± 42
1BnTIQ/25 9 14 6 588 ± 42** 2273 ± 161*
1MeTIQ/25 9 14 5 498 ± 10 2133 ± 100
1MeTIQ/50 9 14 6 520 ± 21 1988 ± 38
1MeTIQ/25 9 14 ? 1BnTIQ/25 9 14 6 477 ± 16?? 1998 ± 55?
1MeTIQ/50 9 14 ? 1BnTIQ/25 9 14 6 530 ± 15 2067 ± 45




1BnTIQ (25 mg/kg i.p.) was administered acute or chronically during 14 consecutive days. 1MeTIQ was
given in two doses (25 and 50 mg/kg i.p.) chronically. In the mixed group, 1MeTIQ was given also
chronically, 20 min before each 1BnTIQ administration. Rats were decapitated 2 h after the injections. The
results are expressed as the means ± SEM of five to seven samples (n = 5–7 animals per group). Data
were analyzed with a one-way ANOVA followed by Duncan’s post hoc test. Statistical significance:
* P\ 0.05; ** P\ 0.01 versus saline group; ? P\ 0.05; ?? P\ 0.01 versus 1BnTIQ group
Fig. 4 The influence of chronic 1MeTIQ administration on 1BnTIQ-
induced changes in a-synuclein level. 1BnTIQ was administered (25
mg/kg i.p.) acute or chronically for 14 consecutive days. In the mixed
group, 1MeTIQ (50 mg/kg i.p.) was administered chronically, 20 min
before 1BnTIQ administration. Control rats were treated with the
appropriate vehicle. Rats were killed by decapitation 2 h after last
drug injections and substantia nigra was dissected for analysis. The
data are expressed as the means ± SEM. (n = 6–7 animals). Data
were analyzed with a one-way ANOVA, followed by Duncan’s post
hoc test. Statistical significance: * P\ 0.05; ** P\ 0.01 versus
saline-treated group; ?P\ 0.05 versus 1BnTIQ-treated group
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metabolism in the rat brain (Wa˛sik et al. 2009). Interest-
ingly, acute treatment with 1BnTIQ produced a stronger
effect on DA metabolism than multiple administration,
which suggests the development of tolerance after the
chronic administration of 1BnTIQ (Table 1). However,
both the single and repeated administration of 1BnTIQ
significantly reduced the DA concentration in the brain
structures, associated with the DA-mediated oxidative
stress, as observed in the surviving dopaminergic terminals
of PD patients (Antkiewicz-Michaluk et al. 2001). Previous
studies have shown that 1BnTIQ strongly potentiates
MAO-dependent DA oxidation, thereby increasing free
radical production and damage to DA cells (Wa˛sik et al.
2009). However, 1BnTIQ inhibits COMT activity and
significantly decreases the concentration of 3-MT, an
extraneuronal metabolite of DA, with a different neuro-
protective effect (Miller et al. 1996). We also present the
first investigation of the influence of the chronic adminis-
tration of 1BnTIQ on the level of the excitatory amino
acids (EAA), aspartate (ASP) and glutamate (GLU), in rat
frontal cortex.
Using this animal model of PD, we investigated the
effect of the neuroprotective endogenous amine, 1MeTIQ.
As an endogenous inhibitor of MAO activity, 1MeTIQ
shifts DA catabolism toward COMT-dependent O-methy-
lation, thereby increasing the concentration of the extra-
neuronal DA metabolite, 3-MT (Antkiewicz-Michaluk
et al. 2001; Patsenka and Antkiewicz-Michaluk 2004).
Indeed, we previously observed that 1MeTIQ possesses
neuroprotective activity in different animal models of
neurodegeneration and protects neurons against glutamate-
and kainite-induced excitotoxicity (Antkiewicz-Michaluk
et al. 2006, 2014).
In the present study, we demonstrated that both the acute
and repeated administration of 1MeTIQ completely
reversed the toxic effects of 1BnTIQ on DA neurons.
Additionally, the chronic administration of 1MeTIQ
antagonized the 1BnTIQ-induced increase of the EAA
concentration in the rat frontal cortex (Table 4). These data
suggest that 1MeTIQ might participate in the EAA trans-
mission; however, in the present study, we investigated the
entire pool of GLU localized in the tissue. The chronic
administration of 1BnTIQ increased the total level of EAA,
potentially leading to excitotoxicity. Psychostimulants,
such as nicotine, also increase the concentration of GLU in
the prefrontal cortex, which increases neuronal activity
(Falasca et al. 2014; Shameem and Patel 2012). The data
from other studies have suggested that the systemic
administration of the well-known neurotoxin 1-methyl-1-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
increases glutamatergic neurotransmission as an essential
step in the evolution of parkinsonian symptoms (Bergman
et al. 1990; Mitchell et al. 1989). The glutamate antagonist
kynurenate reverses akinesia in MPTP-treated marmosets
following focal injection into the medial pallidum
(Brotchie et al. 1991). These results indicate that the
selective reduction of glutamatergic overactivity might be
an effective strategy for the treatment of PD.
The behavioral test showed that chronic treatment with
1BnTIQ significantly elevated the locomotor activity in
rats (Fig. 1). Interestingly, an acute dose of 1BnTIQ
(50 mg/kg i.p.) produced the opposite effect, showing the
reduction of exploratory activity in rats, as previously
demonstrated (Wa˛sik et al. 2009). The hyperactivity of rats
observed after the multiple administration of 1BnTIQ
might reflect the 1BnTIQ-induced impairment of DA
storage, and this reserpine-like inhibition of the function of
vesicular monoamine transporter (VMAT) has been pre-
viously demonstrated in an in vivo microdialysis study
(Wa˛sik et al. 2014). Importantly, both the acute and
chronic administration of 1MeTIQ (50 mg/kg i.p.) com-
pletely antagonized 1BnTIQ-induced hyperactivity
(Fig. 1a, b) and reduced exploratory locomotor activity
below that in the control group. Notably, the development
of tolerance after the repeated administration of 1MeTIQ
was not observed. This effect of 1MeTIQ can be explained
by two mechanisms: (1) As a partial dopamine agonist,
1MeTIQ could block the active conformation of the DA
receptor (Antkiewicz-Michaluk et al. 2014); and (2)
1MeTIQ shifts DA catabolism toward COMT-dependent
O-methylation pathway, thereby significantly increasing
the extraneuronal metabolite concentration of 3-MT (An-
tkiewicz-Michaluk et al. 2001). Moreover, 3-MT shows
Fig. 5 The influence of chronic 1MeTIQ administration on 1BnTIQ-
induced changes in tyrosine hydroxylase concentration. 1BnTIQ was
administered (25 mg/kg i.p.) acute or chronically for 14 consecutive
days. In the mixed group, 1MeTIQ (50 mg/kg i.p.) was administered
chronically, 20 min before 1BnTIQ administration. Control rats were
treated with the appropriate vehicle. Rats were killed by decapitation
2 h after last drug injections and substantia nigra was dissected for
analysis. The data are expressed as the means ± SEM. (n = 6–7
animals). Data were analyzed with a one-way ANOVA, followed by
Duncan’s post- hoc test. Statistical significance: * P\ 0.05;
** P\ 0.01 versus saline-treated group; ?P\ 0.05 versus 1BnTIQ-
treated group
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affinity to the a-adrenergic receptor as an antagonist, and
this molecule might play an important physiological role as
an inhibitory regulator, counteracting the excessive stim-
ulation of catecholaminergic neurons (Antkiewicz-Micha-
luk et al. 2008).
Biochemical studies have shown that the acute and
chronic administration of 1BnTIQ markedly decreased the
dopamine level in the extrapyramidal (striatum) and
mesolimbic (nucleus accumbens) dopamine structures in the
rat brain (Table 1). Post-mortem clinical trials demonstrated
a total degradation of nigrostriatal pathway, but also other
dopaminergic and noradrenergic structures (Tong et al.
2006).The toxic effect of 1BnTIQ was completely blocked
through the acute and chronic administration of 1MeTIQ (25
and 50 mg/kg) in both investigated structures: striatum and
nucleus accumbens (Tables 2, 3). The simultaneous
administration of 1MeTIQ with 1BnTIQ not only restored
the DA concentration to the control level but also decreased
the DOPAC concentration, thereby inhibiting DA oxidation
(Tables 2, 3). Antagonism of 1MeTIQ compared to changes
induced by 1BnTIQ is better marked in the striatum
(Tables 2, 3). We also demonstrated (Figs. 2, 3) that
1BnTIQ significantly elevated both the rate of the final DA
catabolism, calculated as the ratio [HVA]/[DA], and DA
oxidation, calculated as the index [DOPAC]/[DA]. Both the
acute and chronic administration of 1MeTIQ completely
antagonized the effect of 1BnTIQ on the rate of DA cata-
bolism (Figs. 2, 3). The biochemical effects of 1MeTIQ
might reflect the restrictive influence of this molecule on
MAO activity. It has been previously demonstrated that
1MeTIQ acts as a reversible inhibitor of MAO-A and MAO-
B activity (Patsenka and Antkiewicz-Michaluk 2004; Pat-
senka and Michaluk 2004; Antkiewicz-Michaluk et al.
2006). Interesting is that L-deprenyl (which similarly to
1MeTIQ is an MAO inhibitor) decreases the endogenous
1BnTIQ content in the mouse brain (Kotake et al. 1998).
Additionally, we showed that the chronic administration
of 1BnTIQ increased the concentration of both ASP and
GLU in the rat frontal cortex (Table 4). In this case, the
chronic administration of 1MeTIQ at a lower dose (25 mg/
kg) antagonized this effect. These results are consistent
with previous in vitro experiments, demonstrating the
inhibition through 1MeTIQ glutamate-induced excitotoxi-
city, particularly that mediated through NMDA receptors,
and this effect might be an important factor in the mech-
anism of neuroprotection through 1MeTIQ (Antkiewicz-
Michaluk et al. 2006).
The potential neuroprotective activity of 1MeTIQ is of
obvious interest because this compound is present in
mammalian brains (Yamakawa and Ohta 1997, 1999;
Yamakawa et al. 1999). These data are consistent with
in vitro studies reporting that 1MeTIQ prevents the neu-
rotoxic action of the four dopaminergic neurotoxins,
MPTP, 6-OHDA, rotenone, and 1BnTIQ, in cultured
mesencephalic neurons (Kotake et al. 2005). However, in
the present study, acute and chronic treatment with
1BnTIQ did not change the levels of alpha-synuclein pro-
tein in the substantia nigra (Fig. 4). Moreover, the data
obtained in the present study showed no effect of the
repeated administration of 1BnTIQ on the tyrosine
hydroxylase (TH) concentration in the substantia nigra
(Fig. 5). Similar effects were obtained by Abe et al.
(2001a), they reported that administration of 1BnTIQ did
not reduce TH-positive cells in the substantia nigra in
C57BL mouse. Notably, in vitro studies presented different
results from in vivo studies. Shavali et al. (2004) demon-
strated that 1BnTIQ increased a-synuclein expression and
caused nuclear damage in human dopaminergic cells.
Indeed, we should consider that in vivo experiments are not
always consistent with in vitro research using cell culture.
In vivo experiments often demonstrate compensatory
mechanisms that might mask the toxic effects of the sub-
stance used. However, the other authors used TH
immunohistochemistry to establish in vivo a potential
protective effect of 1MeTIQ in the case when the death of
dopaminergic cells was induced by MPP? and TIQ (Abe
et al. 2001b; Parrado et al. 2000). These papers confirmed
the neuroprotective activity of 1MeTIQ, and demonstrated
a significant antagonism of 1MeTIQ against neurotoxin-
induced loss of TH-positive cells in the substantia nigra.
In conclusion, the results obtained in the present study
clearly confirm that 1MeTIQ possesses essential neuro-
protective properties in an animal model of Parkinson‘s
disease. Additionally, the neuroprotective effect of
1MeTIQ did not induce the development of tolerance after
chronic administration and might restore the function of
dopamine neurons, even after partial damage, which sug-
gests their clinical relevance.
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